Latest Articles

Publication Date
Opiranserin (VVZ-149): what's new in analgesics.

Opiranserin (VVZ-149) is a novel non-opioid, non-steroidal intravenous analgesic with triple antagonistic activity at glycine transporter 2 (GlyT2), purine 2 receptor 3 (P2X3), and serotonin receptor (5-HT2A). Its half-maximal inhibitory …

Published: Oct. 2, 2026, midnight
Factors released from the human placentae, including extracellular vesicles, reduce the migration of endometriotic cells: A potential therapeutic for endometriosis.

Endometriosis is characterised by the growth of abnormal endometrial tissue outside the uterus and chronic inflammation. Increasing evidence suggests that placenta extracellular vesicles (EVs) inhibit the growth and migration of …

Published: Sept. 29, 2026, midnight
[Inhibitory effect of phloroglucinol on eutopic stromal cells and ectopic stromal cells from endometriosis and its mechanism].

Objective: To investigate the inhibitory effects of phloroglucinol on eutopic stromal cells and ectopic stromal cells from endometriosis and its molecular mechanism. Methods: The effect of phloroglucinol on the survival …

Published: Sept. 9, 2026, midnight
β-Glucuronidase at the gut-liver interface: Structural selectivity, enterohepatic reactivation, and the pharmacomicrobiomic case for precision inhibition.

β-Glucuronidase (β-G, EC 3.2.1.31) reverses phase II glucuronidation, and microbial β-G at the gut-liver interface reactivates biliary and circulating conjugates, closing enterohepatic loops for drugs, estrogens, bile acids, and bilirubin. …

Published: Sept. 9, 2026, midnight
Research Progress of Histone Deacetylase and Its Inhibitors in Endometriosis.

Endometriosis is a complex chronic inflammatory disease with an unclear etiology and limited treatment options, severely affecting the reproductive health and quality of life of many women. Histone deacetylases (HDACs), …

Published: Sept. 9, 2026, midnight
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Efficacy and Safety of Linustedastat (OG-6219) in Women with Moderate to Severe Endometriosis-Related Pain.

Endometriosis causes pelvic pain, dysmenorrhea (DYS), dyspareunia, and fertility issues. Linustedastat (OG-6219) is an oral, selective inhibitor of 17β-hydroxysteroid dehydrogenase type 1 (HSD17β1), an enzyme involved in local estradiol biosynthesis. …

Published: Sept. 9, 2026, midnight
Immune regulatory networks and gut microbiota-associated targets in endometriosis: an integrative multi-omics and network analysis.

Endometriosis is an estrogen-dependent disorder characterized by chronic inflammation, immune dysregulation, and altered hormone metabolism. Although gut microbiota-derived metabolites have been implicated in shaping immune microenvironments and lesion development, the …

Published: Sept. 8, 2026, midnight
Phytochemicals Modulating Receptor Tyrosine Kinase Signaling Networks in Endometriosis.

Endometriosis is a chronic, estrogen-dependent inflammatory condition that is marked by the growth of lesions outside the uterus, along with angiogenesis, fibrosis, immune dysregulation, and pain sensitization. There is now …

Published: Sept. 7, 2026, midnight
Study on the role of miR-433-3p in the occurrence and development of endometriosis.

This study aims to characterize the expression pattern and biological functions of miR-433-3p in endometriosis. Eutopic and ectopic endometrial tissues were collected from endometriosis patients, and the expression level of …

Published: Aug. 21, 2026, midnight
Identification of potent inhibitors of JUN N-terminal kinases for treatment of endometriosis and associated pain.

Endometriosis, defined as the ectopic growth of endometrial tissue outside of the uterine cavity, is an inflammatory and hormone-dependent disease that causes excruciating pelvic pain, infertility, and significantly decreases quality …

Published: Aug. 19, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!